Plain-English translation of NCT07800104 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atopic Dermatitis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called QX-4533 to see if it is safe and works well for people with moderate-to-severe atopic dermatitis (a serious skin condition that causes intense itching and inflammation). The study has two parts: first, researchers will give the medication to healthy volunteers to make sure it is safe, and then they will test it in patients who actually have the skin condition. Throughout the trial, participants will be closely monitored to check for side effects and to see how well the medication works.
Atopic dermatitis is a chronic skin condition that causes significant discomfort and affects quality of life. Many patients don't respond well to current treatments or can't tolerate them, so researchers are developing this new medication to offer another option for people struggling with this condition.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will take either the new medication or a placebo (inactive pill) by mouth once daily. For healthy volunteers, the study involves receiving a single dose and close monitoring for side effects. For patients with skin disease, the study is longer and includes multiple visits where your skin condition will be assessed, blood tests will be done, and you'll complete questionnaires about your symptoms. Throughout the trial, you'll be under close medical supervision, and researchers will regularly check on your health and how you're responding to the treatment.
AI-generated summary from trial data · Sep 15, 2026 · Not medical advice
China